



ZNF692 Promotes the Progression of Colon Adenocarcinoma by Regulating HSF4 Expression

Zhengpeng Yang, Hao Wu, Defu Dai, Yufeng Yuan, *Xueqian Shao

Department of General Surgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161002, China

*Corresponding Author: Email: doctorshaoxq@163.com

(Received 10 Apr 2023; accepted 18 Jul 2023)

Abstract

Background: Colon adenocarcinoma (COAD) is one of the most common cancer happened in gastrointestinal tract, with the overall incidence rate of 4%-5% among human beings. Like most malignancies, we uncovered the exact mechanisms of the pathogenesis of colorectal cancer yet. Therefore, there is an urgent need to explore the molecules that can be used as diagnostic maker at early stage. In addition, we also need to define the essential factors that related to the prognosis and treatment of the colon carcinoma.

Methods: The study was conducted at the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China in September 2020. The R language was used to identify the differentially expressed genes. We performed receiver operating characteristic curve analysis to determine the diagnostic markers for COAD. The machine learning strategy was used to assess the effectiveness of genes in the diagnosis of COAD. The molecular mechanism and prognostic value of genes were explored by bioinformatics analysis and molecular experiments.

Results: The expression level of heat shock factor 4 (*HSF4*) was significantly elevated in COAD patients ($P=1.89 \times 10^{-29}$), according to The Cancer Genome Atlas (TCGA) database. Additionally, survival analysis showed the higher expression level of the *HSF4* was correlated with the poor prognosis in COAD.

Conclusion: The *HSF4* was the target gene of zinc finger protein 692 (*ZNF692*). *HSF4* might promote the progression of COAD through the apoptosis pathway. It was diagnostic and prognosis maker of COAD. Furthermore, the upstream gene of *HSF4*, *ZNF692*, promotes the progression of colorectal cancer by regulating *HSF4* expression.

Keywords: Colon adenocarcinoma; Biomarker; Heat shock factor 4; Zinc finger protein 692

Introduction

Colon adenocarcinoma (COAD) is common in the digestive system with high morbidity and mortality (1). The incidence of COAD is growing year by year in China, and the involved population are getting younger because of lifestyle and dietary changes in the past decades (2). The pathophysiology of COAD, like that of other malig-

nant tumors, remains largely under investigated. COAD, as we know, is caused by a combination of genetic and environmental elements. Additionally, COAD is affected by a variety of factors, such as the environment, alcohol, cigarette addiction, intestinal homeostasis, diet, and physical activity (3). However, the treatment of COAD is



Copyright © 2023 Yang et al. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

still dominated by surgery, supplemented by radiotherapy and chemotherapy. Moreover, there are considerable individual variances in treatment effect among individuals with COAD. Although there are multiple choices for the COAD treatment, but the flaws of the foregoing strategies are clear in patients with advanced COAD, resulting in a dismal prognosis. With this in mind, the distant lymph node metastasis, peritoneal metastasis, and hematological metastasis are the most common types of postoperative metastasis for COAD, and they are accompanied with local recurrence typically (4, 5). As the fact that the most prevalent cause of therapeutic failure in COAD is hematogenous metastasis. The survival rates of 5 years among the patients, who are suffering with colon carcinoma, with distant, local, or no metastasis are ranging from 10% to 90%, in other words, are negatively correlated. The goal of this study is to find early detection indicators and to investigate the essential factors involved in COAD development and metastasis.

Heat shock factor 4 (*HSF4*) is a histone H3 variation of centromeric nucleosomes, which is necessary for normal chromosomal segregation assembly (6, 7). Artificial overexpressed *HSF4* may lead to its cellular mis-localization, which will cause the dysfunction of the kinetochores, resulting in abnormal chromosomal separation and genomic instability (8-10). Furthermore, the abnormal expression of *HSF4* and abnormalities of the function of *HSF4* caused compromised genomic integrity led to improper cell division to occur, which may induce the development of cancers (11-13). Moreover, *HSF4* nonphysiologically inclusion has been linked to human cancer in the past (14-16). On the other hand, *HSF4*, has only been documented in a few cases of COAD, and may be utilized as a diagnostic and therapeutic target for the disease.

The current study evaluated the involvement of the *HSF4* in COAD progress, by the data from in vitro studies and clinical specimens from patients.

Methods

Data acquisition

Through the collecting of cancer-related omics data, the Cancer Genome Atlas (TCGA) offers a huge, free reference library for cancer research, which is publically accessible through the TCGA Data Portal (<https://cancergenome.nih.gov>). In September 2020, we retrieved the expression matrix of COAD patients as well as pertinent clinical data from the TCGA database.

Reagents and cell culture

COAD cell lines (LS513 , CW2), normal human colon tissue cells (CCD-18CO cells) were all purchased from American Type Culture Collection (ATCC). In a 37 °C incubator with 5% CO₂, RPMI-1640 medium (Solarbio, China) were used to grown the COAD and BEAS-2B cells. Additionally, 10% (v/v) fetal bovine serum (FBS, Noverse), 100 U/mL of penicillin, and 100 µg/mL of streptomycin (Solarbio) were added to the. Within the past three years, short tandem repeat profiling has been used to validate all human cell lines. All of the investigations were done on mycoplasma-free cells.

RNA extraction and qRT-PCR

TRIzol (Invitrogen, Carlsbad, CA, USA) was used to extract the total RNAs, followed the instruction by the manufacturer. 1 µg extracted RNA was reverse transcribed to cDNA, using the Moloney Leukemia Virus Reverse Transcriptase Kit (Madison, Wisconsin, Promega, USA). Then the qRT-PCR was carried out to amplify the samples to analyze mRNA expression level using Green Mix SYBR (Promega) kit. The housekeeping gene, GAPDH was referred to normalize the expression of the samples. Each experiment was repeated three times to determine the FC in the relative expression level, and the data were analyzed using the 2- $\Delta\Delta$ CT method. The primer sequences utilized in this work are included in Table S1. The primers were created by the NCBI website's "pick primer" online tool.

Western blot

COAD cells were lysed in the RIPA buffer (Thermo Fisher Scientific) (Sigma- Aldrich) supplemented with protease inhibitor cocktail. Pierce Protein Assay Kit (Pierce, USA) was utilized to measure the protein concentration in the cell lysates. Proteins were separated by SDS-PAGE gel, then the proteins were transferred to polyvinylidene difluoride (PVDF) membranes. All the primary antibodies used in this study are listed here: MMP2 (Abcam, UK, ab37150), MMP9 (Abcam, ab73734), PLEKHG5 (Sigma-Aldrich), N-cadherin (Abcam, ab76011), Vimentin (Abcam, ab8069), mDia (Santa Cruz, USA, sc-373895), GAPDH (Cell Signaling Technology, USA, 5174). Chemiluminescence (Bio-Rad, USA) was used to quantify proteins in line with the methodology of the manufacturer.

Cell proliferation assay

The viability of the cells was measured by the Cell Counting Kit-8 (CCK-8) assay as indicated by the protocol from the manufacturer. Briefly, the cells were seeded in 96-well plates with appropriate amount of tumor cells. Then the varied amounts of TMZ or a dime-thyl sulfoxide control was incubated with the cells. After that, the CCK-8 solution was supplemented into the wells. Cells were found in a microplate reader at 450 nm of absorbance.

Apoptosis Assay

When cells were treated with various doses of NG52, the apoptosis test was done using the Annexin-Vfluorescein isothiocyanate (FITC)/propidium iodide (PI) staining technique (KeyGen Biotech, Nanjing, China). The tests were conducted in line with the manufacturer's recommendations.

Biological function and pathway enrichment analysis

There are certain genes that are functionally related because of the similar cellular expression distribution. Genes positively correlated with *HSF4* in the selected modules above (shown by Cytoscape 3.6.1) were found by calculating the corre-

sponding topological overlaps. After that, it underwent pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Gene Ontology (GO). Then the enriched bioprocesses and KEGG pathways were obtained using the "clusterprofiler" package of the R/Bioconductor software for further analysis. Furthermore, *HSF4* expression (median value) was utilized to divide TCGA samples into two groups, and gene set enrichment analysis (GSEA) software ([http:// software. broadinstitute. org/ gsea /index.jsp](http://software.broadinstitute.org/gsea/index.jsp)) was utilized to confirm the results of GO and KEGG analysis in the two groups. Notably, GSEA had nominal P-value and false discovery rate (FDR) cut-offs of 0.05 and 0.25, respectively.

Statistical analysis

For statistical analysis, we utilized SPSS 23.0 (IBM Corp., Armonk, NY, USA) or GraphPad Prism 7 (GraphPad Prism, Inc., La Jolla, CA, USA). The final data were presented as the average SD of three separate studies. To compare two or three groups, the Student's *t*-test or ANOVA were utilized, accordingly.

Results

COAD patients and COAD cells had high expression levels of *HSF4*

To explore the function of *HSF4* in COAD, we determined the *HSF4* expression levels in the TCGA database. We discovered the expression level of *HSF4* was considerably higher in COAD patients ($T=1.988$, $P=1.89 \times 10^{-29}$ Fig.1A). Moreover, the sensitivity and specificity of *HSF4* for the diagnosis of COAD in the TCGA database were examined using ROC curve analysis. For COAD, *HSF4* demonstrated a strong diagnostic significance (AUC=0.903 [0.873, 0.927], $P<0.0001$) (Fig. 1B). Furthermore, the efficiency of *HSF4* in diagnosing COAD was then evaluated using logistic regression. After constructing the confusion matrix, the mean of AUC (0.903) on the ROC curve of *HSF4* was calculated (Fig. 1C). The averages for accuracy, precision, recall,

and F1-score were 0.900, 0.924, 0.970, and 0.946 (Fig. 1C). RT-qPCR and western blot results revealed that the COAD cell lines had greater amounts of *HSF4* mRNA and protein levels than that of normal human colon tissue cells (CCD-

18CO cells) (Fig. 1D,E). Taken together, our findings indicated that the *HSF4* performed well in distinguishing COAD samples from normal controls.




Fig. 1: *HSF4* is elevated in COAD patients and COAD cells. (A)TCGA database showed that *HSF4* expression was considerably elevated in COAD patients. (B) ROC curve analysis showed that *HSF4* had high diagnostic significance for COAD. (C). Evaluation metrics of each fold. (D). Western blot was used to detect the protein levels of *HSF4*. (E). RT-qPCR was used to detect the mRNA levels of *HSF4*. **** $P < 0.0001$

Survival analysis of *HSF4* in COAD

In order to explore the relationship between *HSF4* and prognosis of COAD, survival analysis determined that the increased level of *HSF4* was negatively correlated with prognosis or positively correlated with the cancer-related mortality of

COAD patients ($P=0.026$ HR=1.56;95%CI=1.05–2.32 , Fig. 2A,B). Likewise, in 2-, 3-, and 4-year survival, the area under the curve of time dependent ROC curve was 0.635, 0.656, and 0.642 (Fig. 2C).




Fig. 2: Survival analysis of *HSF4* in COAD. (A) *HSF4* expression and the survival time scatter gram of COAD patients; (B) The survival curves for groups with different expression levels of *HSF4*; (C) Time-dependent receiver operating characteristic (ROC) curve of *HSF4* expression in predicting OS of COAD

Knockdown of *HSF4* promoted cell apoptosis and inhibited cell proliferation in vitro

The COAD cell lines LS513, CW2 were transfected with si-*HSF4* and the negative control siRNA (siRNA NC). Then the cell proliferation ability was detected by CCK-8 assay, and it was found that the level of cell proliferation was dra-

matically reduced after *HSF4* knockdown (Fig. 3A). In addition, the GSEA software was utilized to examine the relationship between *HSF4* expression and KEGG pathway gene sets. In fact, the cell apoptosis was shown to be considerably increased (NES= -1.603, P= 0.0029) (Fig. 3B).




Fig. 3: Knockdown of *HSF4* promoted apoptosis and inhibited cell proliferation in vitro. (A). The cell proliferation was measured by CCK-8 assay after *HSF4* knockdown. (B). GSEA analysis showed that apoptosis were significantly enriched. **P< 0.01

HSF4 was the target gene of ZNF692

We discovered that *HSF4* might be the target gene of *ZNF692*, analyzed by the R package “Dorothea”. The expression level of *ZNF692* in TCGA database was shown to be considerably higher in COAD patients. ($T=1.997$, $P=2.606 \times 10^{-31}$ Fig. 4A). Furthermore, RT-qPCR and western blot results revealed that the COAD cell lines had higher level of *ZNF692* mRNA and

protein level than that of normal human colon tissue cells (CCD-18CO cells) (Fig. 4B, C). Additionally, we created a *ZNF692* overexpression construct and transfected it into LS513 cells. Overexpression of *ZNF692* induced *HSF4* expression (Fig. 4D). In contrast, knocking down *ZNF692* with shRNA produced the opposite effect (Fig. 4E), demonstrating that *ZNF692* controls the expression of *HSF4*.




Fig. 4: *HSF4* was the target gene of *ZNF692*. (A) TCGA database showed that *ZNF692* expression was elevated considerably in COAD patients. (B) RT-qPCR indicated that the mRNA level of *ZNF692* was raised in the COAD cell lines compared to those in normal human colon tissue cells (CCD-18CO cells). (C) Western blot revealed that the protein level of *ZNF692* was raised compared to those in normal human colon tissue cells (CCD-18CO cells). (D) We found that overexpression of *ZNF692* did induce the expression of *HSF4*. (E) shRNA-mediated knock-down of *ZNF692* did reduce the expression of *HSF4*. $**P < 0.01$, $***P < 0.0001$

ZNF692 stimulates COAD cell proliferation in a HSF4 dependent manner

HSF4 was knocked down in *ZNF692*-overexpressing LS513 cells to test this theory. The CCK8 experiment revealed that *ZNF692* +

sh-Control LS513 cells proliferated faster than Empty vector + sh-Control LS513 cells, but it was reversed by *HSF4* knockdown (*ZNF692* + sh-*HSF4*) (Fig. 5), suggesting that *ZNF692* increases COAD cell proliferation through *HSF4*.




Fig. 5: *ZNF692* stimulates COAD cell proliferation in a *HSF4* dependent manner. CCK-8 was utilized to assess the proliferation of LS513 cells that were stable in their expression of *ZNF692 + sh-HSF4*. ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Discussion

Actually, COAD is the second-leading cause of carcinoma-related death all over the world (17). The inner epithelial cells of colorectal tissue are generated from endoderm cells through a multi-step process, which are started from normal epithelial cells to adenomatous polyps, then invasive colorectal cancer, also together with the inactivation of tumor suppressor genes and the activation of oncogenes (18). Patients with advanced COAD had a worse treatment response and survival rate than those with early COAD. Specifically, the rates of 5-year survival declining from 50% to 10% in the advanced instances. The most frequent radical treatment for locally advanced COAD is surgical tumor removal; however, for the metastatic carcinoma, which could not be able to cure by the traditional surgical, radiation, or chemotherapy, there is no optional choice to cure it (19). The COAD quantitative investigations show that conversion between stem cells and ma-

lignant carcinoma cells are happened within 10 years, and those carcinoma cells gain the potential to spread nearby tissues in the following 5 years (20). There are about 30%–40% of COAD patients experience recurrence following therapy, so the early and accurate identification is critical for disease management and prevention. Given the clinical hurdles of improving the prognosis of COAD patients with therapeutic techniques, a considerable number of patients getting standard therapy still suffer recurrence. To develop effective treatments, it is critical to uncover novel approaches, particularly molecular markers, for conducting quick colorectal cancer diagnosis and assessments, discovering novel therapy targets, and greater understanding of the fundamental COAD molecular mechanisms.

ZNF692 is the member of Krüppel C2H2 type zinc finger protein family; it contains five repeats of the C2H2-type zinc finger. Functionally, ANF692 may be able to regulate the gene transcription (21-23). In the past decades, there are

growing data suggests that *ZNF692* plays an critical role in tumor initiation and progression (24,25). Additionally, based on the publicly available data from the UALCAN database, *ZNF692* was overexpressed in fourteen different types of cancer, such as head and neck squamous cell carcinoma, renal clear cell carcinoma, COAD, lung squamous cell carcinoma, bladder urothelial carcinoma, lung adenocarcinoma, and prostate adenocarcinoma (26, 27). Furthermore, in four of these cancers, *ZNF692* was linked to a poor prognosis, such as COAD, adrenocortical carcinoma hepatocellular carcinoma, and renal clear cell carcinoma (28). *ZNF692* expression was shown to be strongly connected with advanced stage and poor survival, and to play a significant role in COAD tumor growth (29, 30).

Furthermore, potential oncogenes with diagnostic and prognostic relevance were the focus of this investigation. *HSF4* and *ZNF692* were discovered to be elevated in COAD samples from the TCGA dataset. The mRNA and protein levels of *HSF4* and *ZNF692* were both raised when compared to normal human colon tissue cells, according to RT-qPCR and western blot. High *HSF4* and *ZNF692* expression levels were strongly linked with a poor prognosis in COAD. In addition, *HSF4* gene expression level has a certain prognostic value in the long-term survival of COAD patients, according to a time-dependent ROC curve.

Our results from CCK8 assay suggested that knockdown of *ZNF692* significantly decreased COAD cell proliferation. Moreover, we discovered that overexpression of *ZNF692* induced higher expression of *HSF4*. In contrast, knocking down *ZNF692* with shRNA produced the opposite effect, demonstrating that *ZNF692* regulates the expression of *HSF4*. In this case, through *HSF4* signaling, we observed that *ZNF692* increased COAD cell proliferation.

Conclusion

The expression of *ZNF692* is considerably elevated in COAD tissues and cell lines. Further-

more, *ZNF692* increases colorectal cancer growth by modulating *HSF4* expression. As a result, the current findings clearly imply that *ZNF692* is a carcinogen in COAD and might be a new prognostic marker for the illness.

Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

This work was supported by the Basic research funding for higher education institutions in Heilongjiang Province in 2021(2021-KYYWF-0360).

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Wong KE, Ngai SC, Chan KG, Lee LH, Goh BH, Chuah LH (2019). Curcumin nanoformulations for colorectal cancer: A review. *Front Pharmacol*, 10:152.
2. Edwards BK, Ward E, Kohler BA, et al (2010). Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer*, 116:544–573.
3. Hao Y, Wang Y, Qi M, He X, Zhu Y, Hong J (2019). Risk factors for recurrent colorectal polyps. *Gut Liver*, 14:399-411.
4. Pohl C, Hombach A, Kruis W (2000). Chronic inflammatory bowel disease and cancer. *Hepato-gastroenterology*, 47:57–70.
5. Mehta A, Patel BM (2019). Therapeutic opportunities in COAD: Focus on phosphodiesterase inhibitions. *Life Sci*, 230:15-161.

6. Valdivia MM, Hamdouch K, Ortiz M, Astola A (2009). CENPA a genomic marker for centromere activity and human diseases. *Curr Genomics*, 10(5):326-35.
7. Howman EV, Fowler KJ, Newson AJ, et al (2000). Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. *Proc Natl Acad Sci U S A*, 97(3):1148-53.
8. Heun P, Erhardt S, Blower MD, Weiss S, Skora AD, Karpen GH (2006). Mislocalization of the *Drosophila* centromere-specific histone CID promotes formation of functional ectopic kinetochores. *Dev Cell*, 10(3):303-15.
9. Shrestha RL, Ahn GS, Staples MI, et al (2017). Mislocalization of centromeric histone H3 variant CENP-A contributes to chromosomal instability (CIN) in human cells. *Oncotarget*, 8(29):46781–46800.
10. Zhang W, Mao JH, Zhu W, et al (2016). Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. *Nat Commun*, 7:12619.
11. Zhang W, Karpen GH, Zhang Q (2017). Exploring the role of CENP-A Ser18 phosphorylation in CIN and tumorigenesis. *Cell Cycle*, 16(24):2323–2325.
12. Sharma AB, Dimitrov S, Hamiche A, Van Dyck E (2019). Centromeric and ectopic assembly of CENP-A chromatin in health and cancer: old marks and new tracks. *Nucleic Acids Res*, 47(3):1051-1069.
13. Sullivan LL, Boivin CD, Mravinac B, Song IY, Sullivan BA (2011). Genomic size of CENP-A domain is proportional to total alpha satellite array size at human centromeres and expands in cancer cells. *Chromosome Res*, 19(4):457-70.
14. Athwal RK, Walkiewicz MP, Baek S, et al (2015). CENP-A nucleosomes localize to transcription factor hotspots and subtelomeric sites in human cancer cells. *Epigenetics Chromatin*, 8:2.
15. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA (2012). Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. *Breast Cancer Res*, 14(3):R72.
16. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 68(6):394–424.
17. Arnold CN, Goel A, Blum HE, Boland CR (2005). Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. *Cancer*, 104(10):2035–2047.
18. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR (2017). The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of COAD. *Dis Colon Rectum*, 60(10):999–1017.
19. Jones S, Chen WD, Parmigiani G, et al (2008). Comparative lesion sequencing provides insights into tumor evolution. *Proc Natl Acad Sci U S A*, 105(11):4283–4288.
20. Jeffery M, Hickey BE, Hider PN (2019). Follow-up strategies for patients treated for non-metastatic colorectal cancer. *Cochrane Database Syst Rev*, 9:CD002200.
21. Xing Y, Zhao Z, Zhu Y, Zhao L, Zhu A, Piao D (2018). Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. *Oncol Rep*, 39:2365–2375.
22. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A (1997). Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. *Nature*, 389:876–881.
23. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P (2001). The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. *Cancer Res*, 61:1250–1254.
24. Imoto I, Yuki Y, Sonoda I, et al (2003). Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. *Cancer Res*, 63:5691-5696.
25. Jiang R, Wang JC, Sun M, Zhang XY, Wu H (2012). Zinc finger X-chromosomal protein (ZFX) promotes solid agar colony growth of osteosarcoma cells. *Oncol Res*, 20:565–570.
26. Lai KP, Chen J, He M, et al (2014). Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. *Int J Cancer*, 135:1790–1799.

27. Fang X, Huang Z, Zhou W, et al (2014). The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. *Stem Cells*, 32:2033–2047.
28. Yan X, Shan Z, Yan L, et al (2016). High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients. *Oncotarget*, 7:19680–19692.
29. Robinson MD, McCarthy DJ, Smyth GK (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26:139–140.
30. Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. *Ann Surg Oncol*, 17:1471–1474.